Aphasia
Recent clinical, regulatory, research and industry developments relating to this disease.
Speech and language markers of neurodegeneration: a call for global equity.
Language impairments in people with autoimmune neurological diseases: A scoping review.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q3 2026.
- Q3 2026A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)
- Q1 2027Center for the Study of Aphasia Recovery (C-STAR): Telerehabilitation for Aphasia (TERRA)
- Q3 2027Clinical Study on the Safety and Efficacy of Temporal Interference Stimulation in the Treatment of Post-Stroke Aphasia
Clinical MilestonesViewHide
- 2026-07-06A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)Results expected Q3 2026
- 2026-04-02Center for the Study of Aphasia Recovery (C-STAR): Telerehabilitation for Aphasia (TERRA)Results expected Q1 2027
- 2026-03-24Clinical Study on the Safety and Efficacy of Temporal Interference Stimulation in the Treatment of Post-Stroke AphasiaResults expected Q3 2027
- 2026-09-18Escitalopram and Language Intervention for Subacute Aphasia (ELISA)Primary completion
- 2026-08-01Effects of Aphasia Identification Cards on Comprehension of Aphasic Language by Unfamiliar Communication PartnersPrimary completion
- 2026-09-18ClinicalEscitalopram and Language Intervention for Subacute Aphasia (ELISA)Primary completion
- 2026-08-01ClinicalEffects of Aphasia Identification Cards on Comprehension of Aphasic Language by Unfamiliar Communication PartnersPrimary completion
- 2026-07-06ClinicalA Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)Results expected Q3 2026
- 2026-04-02ClinicalCenter for the Study of Aphasia Recovery (C-STAR): Telerehabilitation for Aphasia (TERRA)Results expected Q1 2027
- 2026-03-24ClinicalClinical Study on the Safety and Efficacy of Temporal Interference Stimulation in the Treatment of Post-Stroke AphasiaResults expected Q3 2027
- 2025-12-31ClinicalDouble Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal DementiaTerminated
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes3
- Aphasia2
- Alzheimer Disease1
- Language Development Disorders1
Leading journals2
- Brain : a journal of neurology1
- Journal of communication disorders1
Leading researchers8
- Blasi DE1
- de Kok D1
- de Leon J1
- García AM1
- Gorno-Tempini ML1
- Llufriu S1
- Rofes A1
- Rook J1
Affiliations (unnormalised)6
- Center for Language and Cognition1
- Center of Neuroimmunology1
- Cognitive Neuroscience Center1
- Global Brain Health Institute1
- Harvard University1
- Latin American Brain Health (BrainLat) Institute1
Reference
Authoritative identity, definition & identifiers.
A cognitive disorder marked by an impaired ability to comprehend or express language in its written or spoken form. This condition is caused by diseases which affect the language areas of the dominant hemisphere. Clinical features are used to classify the various subtypes of this condition. General categories include receptive, expressive, and mixed forms of aphasia.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.